Targets › CD274
83 programs from 64 companies in 990 trials: 590 Phase 2, 232 Phase 1, 136 Phase 3, 32 Phase 4; Oncology, Other, Infectious disease; next expected readout Nov 2026.
Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. (UniProt, Q9NZQ7)
Open in Phaseline: the race on CD274, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | BCG Solution Glucagon-like peptide 1 receptor agonist | GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274 | Phase 4 | Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss … | Nov 2026 |
| M.D. Anderson Cancer Center | [18F]-4FN PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274 | Phase 4 | Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm … | Dec 2026 |
| Shanghai Pulmonary Hospital, Shanghai, China | PD-1/PD-L1 inhibitor PD-1/PD-L1 pathway inhibitor; anti-PD-1 or anti-PD-L1 monoclonal antibody | PDCD1, CD274 | Phase 4 | NSCLC (Non-small Cell Lung Cancer) | Oct 2028 |
| Roche | Atezolizumab Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 3 | Non-Small Cell Lung Cancer; Hepatocellular Carcinoma; Muscle-invasive Bladder Cancer; Unresectable Hepatocellular Carcinoma … | Nov 2026 |
| Merck KGaA | Avelumab Programmed cell death 1 ligand 1 other | CD274 | Phase 3 | Solid Tumors; Locally Advanced or Metastatic Urothelial Carcinoma; Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable; HNSCC … | Nov 2026 |
| AstraZeneca | Durvalumab (MEDI4736) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 3 | Non Small Cell Lung Carcinoma NSCLC; Hepatocellular Carcinoma; Small Cell Lung Cancer; Biliary Tract Cancer … | Nov 2026 |
| Suzhou Suncadia Biopharmaceuticals | Adebrelimab (SHR-1316) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 3 | Locally Advanced or Metastatic Urothelial Carcinoma; PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer; Advanced Biliary Tract Cancer; Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma … | Dec 2026 |
| Akeso | Envafolimab (AK112) Programmed cell death 1 ligand 1 binding agent | CD274 | Phase 3 | Triple-Negative Breast Cancer (TNBC); Advanced Squamous Non Small Cell Lung Cancer; Advanced Non-small-cell Lung Cancer; Colorectal Adenocarcinoma … | Dec 2026 |
| 3D Medicines (Sichuan) | Envafolimab (KN035) Programmed cell death 1 ligand 1 binding agent | CD274 | Phase 3 | Non-small Cell Lung Cancer; Advanced Endometrial Cancer; Solid Tumor; Solid Tumors | Dec 2026 |
| Pfizer | Avelumab Programmed cell death 1 ligand 1 other | CD274 | Phase 3 | Advanced Malignancies | Dec 2026 |
| Biotheus | PM8002 bispecific antibody targeting PD-L1 and VEGF | CD274, VEGFA, PDCD1LG2 | Phase 3 | SCLC; Triple Negative Breast Cancer(TNBC); NSCLC; Neuroendocrine Neoplasm … | Jan 2027 |
| University Hospital, Bordeaux | PD-1/PD-L1 ICI + VEGFR-TKI combination PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor | PDCD1, CD274, KDR, FLT1, FLT4 | Phase 3 | Metastatic Renal Cell Carcinoma | Jan 2027 |
| Genmab | Acasunlimab Bispecific antibody that engages PD-L1 and 4-1BB | CD274, TNFRSF9 | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Jul 2027 |
| IO Biotech | IO102-IO103 Dual peptide antigen cancer vaccine (IDO peptide antigen IO102 and PD-L1 peptide antigen I | IDO1, CD274 | Phase 3 | Metastatic Melanoma | Sep 2027 |
| Amgen | ABP 206 PD-L1 inhibitor | CD274 | Phase 3 | Melanoma | Jan 2028 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQB2868 Injection PD-L1 and TGF-β dual antibody | CD274, TGFB1 | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | May 2028 |
| Sun Yat-sen University | PD-1/PD-L1 inhibitors PD-1 and PD-L1 checkpoint inhibitors | PDCD1, CD274 | Phase 3 | Non-small Cell Lung Cancer | Jul 2028 |
| UNICANCER | Reduced dose intensity of IO Anti-PD-1, anti-PD-L1, or anti-CTLA-4 checkpoint inhibitor | PDCD1, CD274, CTLA4 | Phase 3 | Lung Cancer Metastatic | May 2029 |
| Sun Yat-sen University | PD-1/PD-L1 immune checkpoint inhibitor PD-1/PD-L1 immune checkpoint inhibitor | PDCD1, CD274 | Phase 3 | Locally Advanced Non-Small Cell Lung Cancer | Jun 2029 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Anti-PD-1/PD-L1 Antibody PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 3 | Esophagus Cancer; Esophageal Cancer | Dec 2030 |
| Shanghai Pulmonary Hospital, Shanghai, China | PD-L1/VEGF Bispecific Antibody (PM8002) PD-L1 and VEGF dual-targeting bispecific antibody | CD274, VEGFA | Phase 3 | Locally Advanced Non-Small Cell Lung Cancer | Dec 2033 |
| Biocad | prolgolimab anti-PD-L1 monoclonal antibody | CD274 | Phase 3 | Melanoma | – |
| Shanghai Henlius Biotech | HLX43 anti-PD-L1 antibody-drug conjugate with topoisomerase I inhibitor payload | CD274 | Phase 2 | Nasopharyngeal Carcinoma (NPC); Non Small Cell Lung Cancer; Colorectal Cancer (CRC); Cervical Cancer … | Nov 2026 |
| National Cancer Institute (NCI) | PD-L1 t-haNK cells Engineered natural killer cells expressing PD-L1 | CD274 | Phase 2 | Stage II Squamous Cell Carcinoma of the Head and Neck | Dec 2026 |
| RenJi Hospital | ABSK043 PD-1/PD-L1 interaction inhibitor | PDCD1, CD274 | Phase 2 | HCC - Hepatocellular Carcinoma | Dec 2026 |
| ETOP IBCSG Partners Foundation | Anti-PD-L1 antibody PD-L1 inhibitor | CD274 | Phase 2 | SCLC,Extensive Stage | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | Benmelstobart injection Humanized monoclonal antibody targeting PD-L1 | CD274 | Phase 2 | Non-Small Cell Lung Cancer | Dec 2026 |
| Hunan Cancer Hospital | Sugemalimab Programmed cell death 1 ligand 1 binding agent | CD274 | Phase 2 | Carcinoma, Non-Small-Cell Lung | Dec 2026 |
| National Cancer Institute (NCI) | Bintrafusp Alfa (M7824) Programmed cell death 1 ligand 1 binding agent; Transforming growth factor beta binding agent | CD274, TGFB1, TGFB2, TGFB3 | Phase 2 | Thymic Epithelial Tumor; Cancer Of Prostate; Kaposi Sarcoma; Urothelial Cancer | Dec 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | anti-PD-1 or PD-L1 antibody PD-1/PD-L1 pathway inhibitor | PDCD1, CD274 | Phase 2 | Head and Neck Cancer | Dec 2026 |
| The Second Affiliated Hospital of Chongqing Medical University | anti-PD-1/anti-PD-L1 antibody PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Chronic Hepatitis B | Dec 2026 |
| IO Biotech | IO103 PD-L1 peptide | CD274 | Phase 2 | Melanoma | Jan 2027 |
| ImmuneOncia Therapeutics | Danburstotug (IMC-001) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 2 | Extranodal NK/T-cell Lymphoma, Nasal Type; TMB-H; Subjects With Resectable and Localized Gastric Cancer | Feb 2027 |
| Zhejiang Cancer Hospital | PD-1/PD-L1 inhibitors PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Adjuvant Radiotherapy | Mar 2027 |
| University Health Network, Toronto | ABSK043 PD-L1 inhibitor | CD274 | Phase 2 | Sarcoma | Mar 2027 |
| Sun Yat-sen University | Adebelimab Anti-PD-L1 monoclonal antibody | CD274 | Phase 2 | Resectable Mucosal Melanoma | Mar 2027 |
| Sun Yat-sen University | Sugemalimab Programmed cell death 1 ligand 1 binding agent | CD274 | Phase 2 | Limited Stage Small Cell Lung Cancer | Mar 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | PD-1/PD-L1 inhibitors PD-1/PD-L1 pathway inhibitor | PDCD1, CD274 | Phase 2 | Advanced Malignant Solid Tumor | Apr 2027 |
| West China Hospital | PD-L1 antibody PD-L1 immune checkpoint inhibitor | CD274 | Phase 2 | Hepato Cellular Carcinoma (HCC) | Apr 2027 |
| First People's Hospital of Hangzhou | PD-L1 inhibitor PD-L1 pathway inhibitor | CD274 | Phase 2 | Non-Small Cell Lung Cancer | Apr 2027 |
| ImmunityBio | PD-L1 t-haNK PD-L1-targeted human aNK cell therapy | CD274, PDCD1LG1 | Phase 2 | Pancreatic Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Head and Neck Cancer | May 2027 |
| Fudan University | PD-L1/PD-1 inhibitor and chemotherapy PD-L1/PD-1 checkpoint inhibitors combined with chemotherapy | PDCD1, CD274 | Phase 2 | NSCLC Stage IV | Jul 2027 |
| Jinling Hospital, China | PD-1/PD-L1 ICI + VEGFR-TKI PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor | PDCD1, CD274, KDR | Phase 2 | Renal Cell Carcinoma (RCC) | Aug 2027 |
| Shenyang Sunshine Pharmaceutical | SSGJ-706 PD-1/PD-L1 bispecific antibody | PDCD1, CD274 | Phase 2 | First-line Advanced NSCLC Patients | Aug 2027 |
| Shanghai Hengrui Pharmaceutical | Adebrelimab (SHR-1316) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 2 | Limited-stage Small-cell Lung Cancer; Malignant Solid Tumors; Advanced or Metastatic Non-small Cell Lung Cancer; Locally Advanced or Metastatic Pancreatic Cancer With … | Oct 2027 |
| Eye & ENT Hospital of Fudan University | Finolizumab PD-L1 inhibitor | CD274 | Phase 2 | Hypopharyngeal Carcinoma | Nov 2027 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | benmelstobart PD-L1 inhibitor | CD274 | Phase 2 | Advanced Metastatic Pancreatic Cancer | Dec 2027 |
| Tianjin Medical University Cancer Institute and Hospital | TQB2450 anti-PD-L1 monoclonal antibody | CD274 | Phase 2 | Non-small-cell Lung Cancer | Dec 2027 |
| Henan Cancer Hospital | Envorimab PD-L1 inhibitor | CD274 | Phase 2 | Esophageal Malignant Neoplasm Primary | Dec 2027 |
| Shanghai Pulmonary Hospital, Shanghai, China | Sugemalimab Programmed cell death 1 ligand 1 binding agent | CD274 | Phase 2 | Lung Cancer (NSCLC) | Dec 2027 |
| Chuangzhen Chen | PD-1/PD-L1 monoclonal antibodies PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Radiotherapy | Jan 2028 |
| Changhai Hospital | tuvonralimab PD-L1 inhibitor | CD274 | Phase 2 | MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706 | Aug 2028 |
| City of Hope Medical Center | Anti-PD-L1 Monoclonal Antibody PD-L1 inhibitor | CD274 | Phase 2 | Lung Non-Small Cell Carcinoma | Oct 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | PD-L1 antibody PD-L1 immune checkpoint inhibitor | CD274 | Phase 2 | Lung Cancer | Dec 2028 |
| The First Affiliated Hospital with Nanjing Medical University | PD-1/PD-L1 monoclonal antibody PD-1/PD-L1 pathway inhibitor | PDCD1, CD274 | Phase 2 | Primary Central Nervous System Lymphoma (PCNSL) | Dec 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | PD-1/PD-L1/CTLA-4 inhibitors PD-1, PD-L1, and CTLA-4 checkpoint inhibitors | PDCD1, CD274, CTLA4 | Phase 2 | Head/Neck Neoplasm | Jan 2029 |
| Fudan University | Adebelimab Anti-PD-L1 monoclonal antibody | CD274 | Phase 2 | Advanced HER2-positive Breast Cancer | Feb 2029 |
| Tianjin Medical University Second Hospital | PD-1/PD-L1 Inhibitor PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Bladder (Urothelial, Transitional Cell) Cancer | Mar 2029 |
| UNC Lineberger Comprehensive Cancer Center | PD-1/PD-L1 inhibitor monotherapy PD-1 or PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Lung Cancer | Jan 2033 |
| University of California, Davis | Systemic (ICI)-based therapy informed by PROphet CB assay and CARG-TT assessment anti-PD(L)1 immune checkpoint inhibitor(s), with regimen selection guided by proteomic (PR | PDCD1, CD274 | Phase 2 | Non-small Cell Lung Cancer Stage IIIC | May 2036 |
| Hunan Province Tumor Hospital | IBI318 Bispecific anti-PD-1/PD-L1 antibody | PDCD1, CD274 | Phase 2 | Non-Small Cell Lung Cancer | – |
| Nanfang Hospital, Southern Medical University | PD-L1 inhibitor PD-L1 inhibitor | CD274 | Phase 2 | Small Cell Lung Cancer Extensive Stage | – |
| TILT Biotherapeutics | Avelumab Programmed cell death 1 ligand 1 other | CD274 | Phase 1 | Melanoma | Dec 2026 |
| Betta Pharmaceuticals | BPI-371153 PD-L1 inhibitor | CD274 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| University of California, Davis | IO102-IO103 Peptide Vaccine PD-L1/IDO peptide vaccine activating T-cells against tumor and immune suppressive cells | CD274, IDO1 | Phase 1 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | Dec 2026 |
| Sichuan University | α-PD-L1/4-1BB DLL3 CAR-T (BHP01) dual-targeted CAR-T cell therapy targeting PD-L1 and DLL3 with 4-1BB costimulatory domain | CD274, DLL3 | Phase 1 | Small Cell Lung Cancer Extensive Stage | Dec 2026 |
| China-Japan Friendship Hospital | PD-1/L1 inhibitor PD-1/PD-L1 pathway inhibitor | PDCD1, CD274 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Sichuan University | Dual-targeting VEGFR1/PD-L1 CAR-T cells Bispecific CAR-T cells targeting VEGFR1 and PD-L1 | FLT1, CD274 | Phase 1 | Malignant Peritoneal Effusion | Jun 2027 |
| West China Hospital | PD-1/PD-L1 Inhibitor-Based Therapy PD-1/PD-L1 inhibitor monotherapy or combination therapy | PDCD1, CD274 | Phase 1 | Solid Tumors | Jul 2027 |
| Sichuan University | Sugemalimab Programmed cell death 1 ligand 1 binding agent | CD274 | Phase 1 | Lung Cancer | Oct 2027 |
| Pfizer | PF-08046054/SGN-PDL1V anti-PD-L1 antibody-drug conjugate | CD274 | Phase 1 | Carcinoma, Non-Small-Cell Lung | Jan 2028 |
| M.D. Anderson Cancer Center | Anti-PD-1/PD-L1 PD-1/PD-L1 checkpoint inhibitor monoclonal antibodies | PDCD1, CD274 | Phase 1 | Advanced Malignant Solid Neoplasm | Feb 2028 |
| Shine-On Biomedical | SOA101 Nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3 | CD274, HLA-G, CD3E | Phase 1 | Solid Tumors | Feb 2028 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Pulse radiotherapy combined with PD(L)-1 inhibitors Pulsed radiotherapy combined with PD(L)-1 immune checkpoint inhibition | PDCD1, CD274 | Phase 1 | Non Small Cell Lung Cancer | Jul 2028 |
| Vaccinex | Avelumab Programmed cell death 1 ligand 1 other | CD274 | Phase 1 | Metastatic Pancreatic Adenocarcinoma | Dec 2028 |
| Shanghai Chest Hospital | PD-L1 inhibitor PD-L1 inhibitor | CD274 | Phase 1 | Non-Small Cell Lung Cancer | Dec 2028 |
| AP Biosciences | AP505 Anti-PD-L1 and Anti-VEGF antibody fusion protein | CD274, VEGFA | Phase 1 | Advanced Solid Tumors | – |
| AstraZeneca | Atezolizumab (MEDI4736) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 1 | Ovarian | – |
| Checkpoint Therapeutics | Cosibelimab (CK-301) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 1 | Lung Neoplasms; Cutaneous Squamous Cell Carcinoma | – |
| Sichuan University | Dual-targeting CLDN18.2 and PD-L1 CAR-T cells Dual-targeting CAR-T cells against CLDN18.2 and PD-L1 | CLDN18, CD274 | Phase 1 | Advanced Solid Tumor | – |
| InxMed (Shanghai) | Erfonrilimab (KN046) Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor | CTLA4, CD274 | Phase 1 | Pancreatic Cancer; Digestive System Cancers; HER2-positive Locally Advanced Resectable Gastric Cancer | – |
| Shanghai Huaota Biopharmaceutical | HB0036 Anti-PD-L1 and anti-TIGIT bifunctional molecule | CD274, TIGIT | Phase 1 | Advanced Solid Tumor | – |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | IMM2510 Anti-PD-L1/VEGF bispecific antibody fusion protein | CD274, VEGFA | Phase 1 | Advanced Solid Tumors | – |
Hepatocellular Carcinoma (36) Breast Cancer (20) Non-Small Cell Lung Cancer (16) Lung Cancer (13) Biliary Tract Cancer (11) Pancreatic Cancer (11) Non Small Cell Lung Cancer (11) Bladder Cancer (11) Hepatocellular Carcinoma (HCC) (9) Non-small Cell Lung Cancer (9) Lung Non-Small Cell Carcinoma (9) Intrahepatic Cholangiocarcinoma (9)
small molecule (32), mixed (23), antibody (10), other (6), protein or peptide (2)
Sun Yat-sen University (4) Sichuan University (4) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) Shanghai Pulmonary Hospital, Shanghai, China (3) AstraZeneca (2) West China Hospital (2) Fudan University (2) Pfizer (2) National Cancer Institute (NCI) (2) M.D. Anderson Cancer Center (2) Second Affiliated Hospital of Guangzhou Medical University (2) University of California, Davis (2) IO Biotech (2) ImmuneOncia Therapeutics (1) Akeso (1) ETOP IBCSG Partners Foundation (1) Roche (1) Biotheus (1) Suzhou Suncadia Biopharmaceuticals (1) Shine-On Biomedical (1)
PDCD1 (26) VEGFA (4) CTLA4 (3) KDR (2) FLT1 (2) TGFB1 (2) OPRM1 (2) IDO1 (2) PDCD1LG2 (1) HLA-G (1) CD3E (1) FLT4 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.